Plasma Voriconazole Estimation by HPLC

Chawla, Prerna K.; Dherai, Alpa J.; Ashavaid, Tester F.

doi:10.1007/s12291-015-0507-z

Cited by 22 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Voriconazole was analyzed by reversed‐phase HPLC according to the method as described by Chawla et al, 37 although with small modifications. The mobile phase was acetonitrile‐MilliQ water (7:3 vol/vol).…”

Section: Methodsmentioning

confidence: 99%

Polymer microparticles with a cavity designed for transarterial chemo‐embolization with crystalline drug formulations

et al. 2020

View full text Add to dashboard Cite

Transarterial chemo‐embolization with drug‐eluting embolic beads (DEB‐TACE) is still evolving. Recent developments include the introduction of radiopaque (X‐ray imageable) drug‐eluting particles. Here, we report on conceptually different radiopaque polymeric drug‐eluting embolic particles, which are (i), cross‐linked poly(methacrylates); (ii), radiopaque; (iii), microporous. Furthermore, the particles are not perfectly spherical: they have a large indentation in the sense that they are either a spherical/cup‐shaped or ellipsoid/mouth‐shaped. The micropores and the large indentation can confer useful features upon the particles, since they can be filled with a crystalline lipophilic chemotherapeutic drug. It is important, in this respect that (i), many potent chemotherapeutics are lipophilic and crystalline; (ii), available drug‐eluting beads (DEBs) have the limitation that they can only be used in combination with water‐soluble chemotherapeutic agents. Cup‐ and mouth‐shaped particles were obtained in a Cu(0) catalyzed free‐radical polymerization reaction. The microparticles could be charged with crystalline drug, in such a manner that the crystals reside in both the micropores and the large cavity, and in quantities that would be required for effective local chemotherapy. The antifungal drug voriconazole, lipophilic, and crystalline, was used to demonstrate this. We believe that the ability of the microporous/cavitated DEBs to carry lipophilic chemotherapeutic drugs is especially important. DEB‐TACE is likely to become a cornerstone method of interventional oncology in the years ahead, and the new embolic particles described herein hold the promise of becoming scope widening for the technique.

show abstract

Section: Methodsmentioning

confidence: 99%

Polymer microparticles with a cavity designed for transarterial chemo‐embolization with crystalline drug formulations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the crossover study with one week apart as washout period, 5 ml of the optimized formulation (test) containing an equivalent of 40 mg VCZ/kg was orally administered to one group using a stomach sonde needle while 5 ml of the pure drug solution (reference) was given to the other group. Blood samples (1.5 ml) were withdrawn via a cannula from the marginal ear vein of rabbits and collected in heparinized tubes at the time intervals of 0, 1, 2, 3, 4, 5, 8, 10 and 12 h. Quantification of VCZ in rabbit plasma was done using the HPLC method mentioned in the previous section 32 . The software for Pharmacokinetics/ Pharmacodynamics analysis, Kinetica 5.0 was utilized to calculate the pharmacokinetic parameters.…”

Section: In-vivo Pharmacokinetic Studies On New Zealand Male Rabbitsmentioning

confidence: 99%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

Development of a sustained release liquid oral in-situ gel of Voriconazole with improved bioavailability has been the main aim of this project. Complexation of the drug with hydroxypropyl betacyclodextrin was done to improve the solubility and stability of the drug. The mucoadhesive polymer carbopol 934P and release retardant HPMC E50 were used as factors, and a two-square factorial design was employed. A simple mixing method was used for the formulation, and evaluation was done. The polymers had a significant effect on gelation time, mucoadhesive strength, and 8 h drug release. Carbopol showed a better-controlled release and mucoadhesive strength than HPMC E50. The experimental values for gelation time, mucoadhesive strength, drug release at 1 h, 8 h, 12 h, and gel strength were found to be 80 sec, 17453 dynes/cm, 21.10%, 62.98%, 90.54%, 55 sec respectively, which were close to the predicted values. Pharmacokinetic studies revealed a 12 h sustained drug release, plasma drug concentrations above 0.5µg/ml (MIC) and 6.76-fold increase in bioavailability. Thermal and photostability studies revealed a shelf life of 2 years. Equivalence testing proved that the prepared formulation was better than the reference as the ϴtest (0.6835) < ϴstd (0.7963). An elegant, needle-free liquid oral in-situ gel of Voriconazole could thus be successfully developed by statistical optimization techniques using mucoadhesive polymers to sustain the drug release up to 12 h, improve bioavailability and patient compliance.

show abstract

“…Global incidence of invasive aspergillosis is 300,000 cases annually (50% of them are in Asian countries), and the mortality rate is 30-80% [4]. Voriconazole (VRZ) is a second-generation antifungal agent which is a broad-spectrum derivative of fluconazole [5,6]. is agent is available as oral and intravenous (IV) formulations [7].…”

Section: Introductionmentioning

confidence: 99%

“…e oral bioavailability, protein binding, and tissue penetration of VRZ are 96%, 58%, and 2-4.6 L/kg, respectively [9]. VRZ is metabolized by hepatic CYP450 isoenzymes [2,6] and has complicated and nonlinear pharmacokinetic characteristics [2]. e plasma concentration of this drug is unpredictable and varies within and between individuals [10] regardless of the route of administration [11].…”

Section: Introductionmentioning

confidence: 99%

Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis

Yousefian

Dastan

Marjani

et al. 2021

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Purpose. Invasive aspergillosis is a prevalent fungal disease, especially in Asian countries with a high mortality rate. Voriconazole (VRZ) is the first choice for invasive aspergillosis treatment. Plasma concentration of this drug is unpredictable and varies among individuals. This variability is influenced by many factors leading to clinical implication. Therapeutic drug monitoring (TDM) may have a crucial role in the patients’ treatment process. The HPLC method provides sufficient specificity and sensitivity for plasma VRZ concentration determination for TDM purposes of this drug. Methods. Patients who initiated oral or intravenous VRZ for invasive aspergillosis were enrolled in this study. Demographic characteristics and clinical data, outcome, and adverse effects were documented. For each patient, the plasma sample was collected under steady-state condition and analyzed using a validated HPLC method. Results. A total of 22 measurements were performed. Fifty percent of patients were out of the therapeutic range. From them, 27.27% and 22.73% were in subtherapeutic and supratherapeutic ranges (<1 μg/mL and >5.5 μg/mL), respectively. There was a significant correlation between VRZ plasma concentration and treatment outcomes ( P = 0.022 ). Treatment failure was five times higher than treatment success in those in the subtherapeutic range. Adverse effects were observed more frequently in patients with supratherapeutic concentrations compared to those with non-supratherapeutic levels. Furthermore, the mortality rate in patients experiencing treatment failure was 2.17 times higher than those with treatment success. Conclusions. TDM of VRZ plays an important role in better evaluation of efficacy and toxicity during treatment. Therefore, determination of the drug level may be of clinical significance.

show abstract

Plasma Voriconazole Estimation by HPLC

Cited by 22 publications

References 20 publications

Polymer microparticles with a cavity designed for transarterial chemo‐embolization with crystalline drug formulations

Polymer microparticles with a cavity designed for transarterial chemo‐embolization with crystalline drug formulations

Untitled

Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis

Contact Info

Product

Resources

About